Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- MACD is crossing MACD signal line at 0.2. MACD crossing signal line is bullish signal.
|Earning Growth (QoQ)||-93%|
|Revenue Growth (QoQ)|
|Held by Institutions %||96%|
|1 Day Vol Adjusted Return||0.2|
|1 Month Vol Adjusted Return||2.5|
|3 Month Vol Adjusted Return||10.0|
|6 Month Vol Adjusted Return||7.0|
|20 Days SMA Price ZScore||1.4|
|50 Days SMA Price ZScore||1.8|
|12 -26 Days PPO||3.8|
|1 Month Average Short Volume Ratio||47.1|
|1 Day Volume Change ZScore||0.0|
|1 Month Daily Vol||4.6|
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 3) Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) Bausch Health Companies Inc. (NYSE: BHC) ENDRA Life Sciences Inc. (NASDAQ: NDRA) iTeos Therapeutics, Inc. (NASDAQ: ITOS) Magenta Therapeutics, Inc. (NASDAQ: MGTA) (reacted to fourth-quarter results) MiMedx Group, Inc. (NASDAQ: MDXG) Renalytix AI plc (NASDAQ: RNLX) Down In The Dumps (Biotech Stocks Hitting 52-...
Luminex Corporation (NASDAQ: LMNX) today announced that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a new expanded version of its NxTAG® Respiratory Pathogen Panel (RPP) that includes the SARS-CoV-2 virus for high-throughput respiratory testing. The new test is a combination of the company's original NxTAG RPP, an FDA-cleared in vitro diagnostic for syndromic respiratory infection testing, and SARS-CoV-2.
Luminex (LMNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Investor confidence is high in Luminex (LMNX) stock, courtesy of its solid prospects.
Luminex Corporation (NASDAQ: LMNX) has received .3 million in funding from the Biomedical Advanced Research and Development Authority (BARDA). It will support the rapid development and validation of a respiratory panel combining Flu A/B & respiratory syncytial virus targets with the SARS-CoV-2 target that can run on all ARIES Systems. These six and 12-cassette systems are automated molecular diagnostic platforms and produce results in less than two hours. Luminex developed the original ARIES SAR...
Luminex Corporation (NASDAQ: LMNX) today announced that it has received $11.3 million in funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. These funds will support the rapid development and validation of a respiratory panel combining Flu A/B & respiratory syncytial virus (RSV) targets with the SARS-CoV-2 target that can be run on all ARIE...